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implementation of a prescribing guideline.Methods: We conducted a retrospective analysis to eval-
uate the impact of a prescribing guideline on usage patterns of dexmedetomidine in the operating
room at a tertiary, academic medical center during one-month period pre- (July 2010) and post-
guideline (July 2011 and July 2012) implementation. Results: A total of 267 patients received intra-
operative dexmedetomidine during the study period. Dexmedetomidine use in surgical procedures
decreased post-guideline implementation [5.7% (pre) vs. 1.9% and 3.3% (post)]. The most common
guideline-based indication for intraoperative dexmedetomidine was for anesthesia during bariatric
surgery (41% and 38% in 2011 and 2012, respectively). We estimated a cost-avoidance of $308,856
over the two-year period after guideline implementation. Conclusion: Our results suggest that imple-
mentation of a prescribing guideline for the use of dexmedetomidine in the operating room is fea-
sible and associated with improved utilization patterns.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prescribing guidelines have become a standard component of
clinical practice over the past decade. A previous trial demon-
strated that implementation of a prescribing guideline in theoperating room (OR) was associated with improvement in
the appropriateness of neuromuscular blocker and sedative
use, as well as cost savings. However, data demonstrating
the impact of prescribing guidelines in the OR remain limited
(Higgins et al., 1997).
The use of dexmedetomidine during surgical procedures has
increased over time (Carollo et al., 2008). Dexmedetomidine
hydrochloride1 is a centrally selective, a2-adrenergic receptor
agonist. It provides sedative, hypnotic, anxiolytic, sympa-
tholytic, and analgesic properties without affecting theine at a
Table 1 Summary of the dexmedetomidine prescribing guide-
line in the operating room.
Dexmedetomidine is a restricted agent in the operating room and
should only be used according to the guidelines outlined below
A. Use in the operating room
1. Awake ﬁbre-optic intubation
2. Awake craniotomy
3. Surgical procedures in patients with body mass index (BMI)
greater than 40 kg/m2
4. Bariatric surgery in patients with BMI greater than 35 kg/m2
5. Surgical procedures when deemed medically appropriate by
anesthesiologist
i. Oﬀ-guideline usage patterns will be evaluated monthly
by anesthesia and pharmacy
B. Duration of therapy
1. Dexmedetomidine is not indicated beyond the length of the
surgical procedure
2. Requests for continued use of dexmedetomidine beyond the
surgical procedure must be reviewed by the clinical team,
2 A.M. Alhammad et al.respiratory drive (Szumita et al., 2007). Dexmedetomidine was
initially approved for sedation of mechanically ventilated
patients in the intensive care unit (ICU) for up to 24 h. The
indications were updated in 2008 to include sedation of non-
intubated patients prior to and/or during surgical and other
procedures (Precedex, 2014). While pharmacological proper-
ties of dexmedetomidine make it suitable for use in the OR,
safety and efﬁcacy data from randomized trials are available
for speciﬁc surgical indications (Bergese et al., 2010a,b;
Bekker et al., 2008; Turgut et al., 2009; Tufanogullari et al.,
2008; Feld et al., 2006).
In 2010, an internal analysis of dexmedetomidine utilization
at a 793-bed tertiary academic medical center showed that this
medication was being used during a variety of surgical proce-
dures. In response to this analysis, a team of pharmacists and
anesthesiologists developed and implemented a prescribing
guideline to optimize utilization of this costly resource in the
OR. The purpose of this study was to evaluate the impact of
the prescribing guideline on usage patterns of dexmedeto-
midine in the OR over three time points.including the attending intensivist and pharmacist2. Methods
The prescribing guideline was implemented by a multidisci-
plinary team in the spring of 2011 (Table 1). Upon request
for dexmedetomidine during the OR pharmacy business hours,
the anesthesiologist used a paper form to document the indica-
tion for therapy.
A retrospective chart review of adult patients who had
received dexmedetomidine in the OR during July 2011 and
July 2012 (post-guideline implementation) was performed.
Data previously collected for July 2010 (pre-guideline imple-
mentation) were used as the comparator group. A hospital
database was used to identify all adult patients who had under-
gone a surgical procedure and were charged for dexmedeto-
midine during the study periods. Patients were excluded if
the medical record was incomplete or unavailable. This study
was approved by our institution’s Institutional Review Board.
The paper request form and electronic medical records for
all patients were reviewed for relevant information including:
demographic information, American Society of Anesthesiolo-
gists Physical Status Classiﬁcation System, dexmedetomidine
indication for use, dose, length of therapy, type of surgical pro-
cedure, duration of surgery, hospital and ICU length of stay
(LOS), and hospital and ICU mortality. The primary endpoint
was the number of surgical procedures in which dexmedeto-
midine was used pre- and post-guideline implementation. Sec-
ondary endpoints included dexmedetomidine use by surgical
service (pre- and post-guideline implementation), dexmedeto-
midine use by surgical procedure (post-guideline implementa-
tion), and cost utilization.3. Results
A total of 326 patients who received dexmedetomidine in the
OR in July 2010, July 2011, and July 2012 were evaluated
for participation in the study. Fifty-nine patients were
excluded, for a total enrolment of 267 patients (representing
267 surgical procedures). Baseline characteristics were similar
amongst the patients in all three groups (Table 2).Please cite this article in press as: Alhammad, A.M. et al., Evaluation of the impac
tertiary academic medical center. Saudi Pharmaceutical Journal (2016), http://dx.do3.1. Impact of the prescribing guideline on dexmedetomidine
utilization
Dexmedetomidine was used in 5.7% (July 2010), 1.9% (July
2011), and 3.3% (July 2012) of surgical procedures during
the study periods. Prior to implementation of the guideline,
the highest users of intraoperative dexmedetomidine were car-
diac surgeries (56%) followed by bariatric surgeries (20%).
Post-implementation, cardiac surgery procedures represented
only 11% and 5% of total intraoperative dexmedetomidine
use in 2011 and 2012, respectively. Overall, the use of intraop-
erative dexmedetomidine was mostly in accordance with the
guideline. The most common guideline-based indication for
dexmedetomidine was bariatric surgery in patients with body
mass index (BMI) > 35 kg/m2 (41% and 38% in 2011 and
2012, respectively).
Dexmedetomidine was used off-guideline as deemed ‘medi-
cally appropriate’ by the anesthesiologist in 21% and 27% of
cases in 2011 and 2012, respectively. Rationale reported by the
anesthesiologist included allergy to other anesthetics and med-
ications, severe bronchospastic lung disease, alcoholism, and
opioid abuse.
3.2. Impact of the prescribing guideline on cost outcomes
The acquisition cost for dexmedetomidine was higher in the
pre-guideline group ($18,709 [July 2010]) than in both post-
guideline groups ($3577 [July 2011] and $8103 [July 2012]).
Using raw data from July 2010, we anticipated an annual
dexmedetomidine expenditure of $224,508 without implemen-
tation of a prescribing guideline. We then estimated the annual
cost after implementation of the prescribing guideline by
extrapolating from raw data from July 2011 and July 2012.
The annual dexmedetomidine cost post-guideline implementa-
tion was $42,924 and $ 97,236, respectively. This represents a
cost-avoidance of $308,856 over the two-year period post-
guideline implementation.t of a prescribing guideline on the use of intraoperative dexmedetomidine at a
i.org/10.1016/j.jsps.2016.01.002
Table 2 Patient baseline demographics and clinical characteristics.
Pre-implementation Post-implementation
July 2010 (n = 144) July 2011 (n = 44) July 2012 (n = 79)
Age  yearsa 50 ± 15 48 ± 14 52 ± 14
Male  n (%) 77 (54) 23 (52) 32 (41)
Weight (kg)a 91 ± 28 122 ± 34 102 ± 31
ASA physical status classification (%)
Class I 1.4 0 0
Class II 27.8 36.4 44.3
Class III 59.7 61.4 51.9
Class IV 11.1 2.3 3.8
Class V 0 0 0
Class VI 0 0 0
Surgical procedures in which dexmedetomidine was used (%)b 5.7 1.9 3.3
Bolus administered  n (%) 57 (39.6) 10 (22.7) 16 (20.3)
Bolus dose (mcg/kg)a 1 ± 0.3 0.6 ± 0.4 0.6 ± 0.5
Initial infusion rate (mcg/kg/h)a 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2
Total dose administered (mcg)c 169 (98–254) 100 (59–161) 106 (66–159)
Length of therapy (min)c 135 (90–195) 100 (45–161) 130 (80–180)
Duration of surgery (min)c 360 (216–435) 159 (138–240) 195 (160–324)
Postoperative status
Inpatient ICU admission – n (%) 87 (60.4) 7 (15.9) 16 (20.5)
Inpatient non-ICU admission – n (%) 51 (35.4) 32 (72.7) 56 (70.9)
Day surgery – n (%) 6 (4.2) 5 (11.4) 7 (8.9)
Length of stay – daysa
ICU 5.4 ± 6.0 2.1 ± 0.9 1 ± 3
Hospital 9.5 ± 7.6 4.5 ± 4.8 5.6 ± 5.5
Mortality – n (%)
ICU 2 (1.4) 0 0
Hospital 2 (1.4) 0 0
Note: ASA= American Society of Anesthesiologists Physical Status Classiﬁcation System; ICU= intensive care unit.
a Values are expressed as mean ± SD.
b Total surgical procedures: July 2010 = 2518; July 2011 = 2247; July 2012 = 2359.
c Values are expressed as median (interquartile range).
Impact of intraoperative dexmedetomidine guideline 34. Discussion
To our knowledge, this is the ﬁrst study to examine the impact of
a prescribing guideline on usage patterns of dexmedetomidine
intraoperatively.We demonstrate that implementation of amul-
tidisciplinary, evidence-based guideline in the OR can improve
adherence to appropriate indications while decreasing the costs
associated with the use of dexmedetomidine intraoperatively.
Our study has several limitations. First, we did not evaluate
surgery-speciﬁc clinical outcomes, such as incidence of respira-
tory depression or recovery room time, which limits the ability
to evaluate the overall impact of the decrease in dexmedeto-
midine utilization. Second, we noted a relatively high use of
dexmedetomidine for non-guideline indications. Data obtained
from the medication request form can help departments assess
whether additional indications should be incorporated into the
guideline, or whether a particular prescriber should be con-
tacted to discuss appropriate guideline-based use. Lastly, due
to stafﬁng considerations, the OR pharmacy at our institution
is not open around the clock, and therefore direct pharmacist
intervention with anesthesiology did not occur for every single
medication request.Please cite this article in press as: Alhammad, A.M. et al., Evaluation of the impac
tertiary academic medical center. Saudi Pharmaceutical Journal (2016), http://dx.do5. Conclusion
Our results provide suggestive evidence regarding the ability of
a prescribing guideline to improve medication utilization in the
OR. More studies are warranted to further identify appropri-
ate indications for dexmedetomidine in the OR.Authors’ contribution
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